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Histone deacetylases (HDACs) regulate chromatin status and
gene expression, and their inhibition is of significant therapeu-
tic interest. To date, no biological substrate for class IIa HDACs
has been identified, and only low activity on acetylated lysines
has been demonstrated. Here, we describe inhibitor-bound and
inhibitor-free structures of the histone deacetylase-4 catalytic
domain (HDAC4cd) and of anHDAC4cd active sitemutantwith
enhanced enzymatic activity toward acetylated lysines. The
structures presented, coupled with activity data, provide the
molecular basis for the intrinsically low enzymatic activity of
class IIa HDACs toward acetylated lysines and reveal active site
features thatmay guide the design of class-specific inhibitors. In
addition, these structures reveal a conformationally flexible
structural zinc-binding domain conserved in all class IIa
enzymes. Importantly, either the mutation of residues coordi-
nating the structural zinc ion or the binding of a class IIa selec-
tive inhibitor prevented the association of HDAC4 with the
N-CoRHDAC3 repressor complex. Together, these data sug-
gest a key role of the structural zinc-binding domain in the reg-
ulation of class IIa HDAC functions.
Eukaryotic histone deacetylases (HDACs)3 were initially dis-
covered in transcriptional repressor complexes, where they
deacetylate acetylated lysines in histone N termini (1). Histone
deacetylation is thought to promote the tight histone-DNA
interactions characteristic of nucleosomes in condensed chro-
matin, where access to DNA for processes including transcrip-
tion, DNA repair, recombination, or replication is limited.
More recently, HDACs have also been shown to deacetylate
nonhistone proteins, predominantly transcription factors
(2–5).Due to their critical role in regulation of chromatin struc-
ture and gene expression, HDACs have become major drug
targets. Indeed, several HDAC inhibitors have entered clinical
trials (6, 7), and one compound, suberoylanilide hydroxamic
acid, was recently approved for the treatment of cutaneous
T-cell lymphomas.
There are currently 18 knownmammalian HDACs, grouped
into four classes based on sequence similarity (8). The class I, II,
and IV HDACs are zinc-dependent enzymes, whereas class III
HDACs (SIRT1–SIRT7) require NAD for activity. The class I
HDACs (HDAC1, -2, -3, and -8) are400 residues long and are
generally nuclear, whereas the class II HDACs (HDAC4, -5, -6,
-7, -9, and -10) exhibit nucleocytoplasmic shuttling. In turn,
class II HDACs are subdivided into class IIa (HDAC4, -5, -7,
and -9) and IIb (HDAC6 and -10). Class IIa enzymes are char-
acterized by the presence of an N-terminal extension of 600
residues with distinct regulatory and functional properties,
whereas the class IIb enzymes contain two catalytic domains
(9–11). Class IV currently includes only HDAC11, which
shares greatest sequence similarity to the class I enzymes.
HDACs have been extensively studied, but the function of
the class IIa enzymes is only partially understood. The most
well characterized roles of class IIa HDACs are as transcrip-
tional repressors, often resulting in the suppression of cellular
hypertrophy (reviewed recently in Refs. 12 and 13). For exam-
ple, HDAC4 was shown to regulate chondrocyte hypertrophy
and skeletogenesis, an activity at least partially exerted through
a repressive interaction with the transcription factor RUNX2
(14, 15). Although RUNX2 has been implicated as a substrate
for deacetylation by HDAC4 and -5 (16), the involvement of a
class IIa deacetylase activity has not been demonstrated. Fur-
ther, HDAC4 was shown to form a complex with HDAC3 via
N-CoR, but therein the catalytic domain of HDAC4 did not
contribute to the enzymatic activity toward acetylated histone
peptides (17). Consistently, we recently reported that class IIa
HDACs possess only weak, but measurable, lysine deacetyla-
tion activity in vitro (18).
For a long time, structural information on zinc-dependent
HDACcatalytic domains has been limited to a bacterialHDAC-
like protein (HDLP) resembling a class I enzyme (19), a eukary-
otic class I enzyme (HDAC8) (20, 21), and a bacterial HDAC-
like amidohydrolase (HDAH) resembling a class IIb enzyme
(22, 23). However, recent progress includes the structures of a
catalytically dead HDAC8 active site mutant bound to an
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acetyl-lysine peptidic substrate (24) and the class IIa HDAC7
catalytic domain (25).
Here we report the crystal structures of the HDAC4 catalytic
domain (HDAC4cd) and of an active site mutant (H976Y) with
enhanced activity toward acetylated lysines, both in complexes
with two different inhibitors. Moreover, we present the struc-
ture of an inhibitor-free HDAC4cd. These structures reveal a
flexible structural zinc-binding domain conserved in all class
IIa enzymes. Mutagenesis, activity, and binding data suggest a
key role of this domain in substrate recognition and in the asso-
ciation of HDAC4 with the HDAC3N-CoR co-repressor com-
plex. In addition, the structures and accompanying activity data
provide the molecular basis for the intrinsically low enzymatic
activity of class IIaHDACs toward acetylated lysines and for the
design of class-selective HDAC inhibitors.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—The human HDAC4
catalytic domain (residues Thr648–Thr1057) was produced in
Escherichia coli BL21 cells using the pETM-11 vector (EMBL
Heidelberg) and was purified via a His6 tag later removed by a
solubility-enhanced TEV protease (26). The complete expres-
sion and purification protocol is given in the supplemental
materials.
Deacetylation Assays—Deacetylation assays were performed
as reported previously using either the “Fluor de Lys” acetamide
substrate (BIOMOL International) or the trifluoroacetamide
substrate (18), which both comprise an acetylated lysine side
chain and a methyl-coumarin group. Deacetylation sensitizes
the substrate so that treatment with the “Fluor de Lys” devel-
oper produces a fluorophore.
Crystallization of the HDAC4 Catalytic Domain—Prior to
crystallization screening of protein-inhibitor complexes, the
HDAC4cd was incubated for 30min at 4 °C with a 3-fold molar
excess of inhibitor dissolved in DMSO. The synthesis of inhib-
itors used has been reported elsewhere (27). Crystals of protein-
inhibitor complexes were obtained by the hanging drop vapor
diffusion technique. Drops were mixed to contain 1 l each of
protein-inhibitor complex at 6–8mg/ml and reservoir solution
containing 1.6 M ammonium sulfate, 0.1 M MES buffer, pH 6.5,
10% dioxane, and 1 mM dithiothreitol. Crystals of HDAC4cd-
inhibitor complexes grew after 2 days of equilibration at 18 °C.
Thewild type (WT) crystals belonged to theC2221 space group
with one molecule per asymmetric unit, whereas the cysteine-
mutant crystals belonged to the P21 space group with twomol-
ecules per asymmetric unit. The two crystal forms have an
almost identical crystal packing; the noncrystallographic 2-fold
axis relating two HDAC4cd molecules in the P21 space group
becomes crystallographic in the C2221 space group (Table S1).
After preincubating the protein with a molar excess of sub-
strate for 30 min at 4 °C, crystals of the inhibitor-free “gain of
function mutant” (GOF) HDAC4cd protein were obtained in
6–8 h. Crystals were not obtained if substrate was omitted. The
inhibitor-free crystals grew in 0.1 M Hepes, pH 7.5, 18% poly-
ethylene glycol 10,000, 1 mM dithiothreitol.
Data Collection, Structure Determination, and Refinement—
X-ray diffraction data were collected at the ID14, BM30, and
ID29 beam lines at ESRF (Grenoble, France) from single crys-
tals flash-frozen in liquid nitrogen. Data were indexed and inte-
grated with MOSFLM (28). The CCP4 program suite (29) was
used for further data processing and analysis.
The structure of WT HDAC4cd-trifluoromethylketone
(TFMK) complex was solved by the single anomalous disper-
sion method. A 2.5 Å resolution data set was collected at the
absorption peak for zinc as determined by x-ray fluorescence.
The position of the zinc ion was located in an anomalous
Patterson map. A combination of single anomalous dispersion
phasing and electron density modification as implemented in
CNX (Accelrys Software Inc.) yielded an interpretable electron
density map. Several cycles of model building in Coot (30) and
positional restrained refinement in REFMAC (29) allowed
building of the entire model, excepting the N- and C-terminal
regions Thr648–Pro650 and Glu1051–Thr1057.
The structures of the complex with the HA and of the other
HDAC4cdmutants were solved bymolecular replacementwith
Phaser (29), using as a searchmodel the refinedWTHDAC4cd-
TFMK complex after removal of the inhibitor, side chains of
active site residues, and loops containing residues involved in
binding the structural zinc ion. When the data resolution was
better than 2.5 Å, the electron density maps were improved
using Arp/Warp in Molrep mode (31). All of the structures
were refined using restrained positional refinement, isotropic
B-factor refinement, and bulk solvent correction with a maxi-
mum likelihood target as implemented in REFMAC. Structure
quality and Ramachandran statistics were assessed usingMol-
probity (32); images were prepared with PyMol (DeLano Scien-
tific LLC).
Iodoacetamide Alkylation Protection Experiments—Alkyla-
tion reaction experiments were performed by incubating 20M
WT HDAC4cd in buffer containing 25 mM Hepes, pH 7.5, 150
mM KCl, 0.1% n-octyl--glucopyranoside with 200 M iodoac-
etamide in the dark for 1 h at room temperature. Following the
reaction, excess iodoacetamide was removed by dialysis. Prior
to analysis by mass spectrometry, 10-g aliquots of the alky-
lated HDAC4 samples and nonalkylated HDAC4 controls
were incubated overnight at 37 °C with 0.4 g of trypsin in
100 mM ammonium bicarbonate, pH 8.0, in 30 l. Subse-
quently, 1 l of each sample was mixed with 1 l of matrix
solution (cyano-4-hydroxycinnamic acid in CH3CN plus
0.1% trifluoroacetic acid (10 mg/ml)) and loaded directly
onto the matrix for analysis by matrix-assisted laser desorp-
tion ionization time-of-flight spectrometry.
In the alkylated and digested WT HDAC4cd sample, we
observed that the peptide containing both Cys667 and Cys669
had reacted with two molecules of iodoacetamide. Likewise, a
peptide containing Cys751 had reacted with one molecule of
iodoacetamide.We did not identify a Cys667/Cys669-containing
peptide that had reactedwith only one alkylated group. In addi-
tion, we found that cysteines buried in the structure were not
alkylated. These results suggest that in solution, Cys667 and
Cys669 are both exposed to the alkylating agent, and thus nei-
ther is protected by binding to the zinc ion.
Mammalian Cell Expression of Full-length HDAC4-FLAG—
HEK293 cells, maintained in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% fetal bovine
serum, were transfected using Lipofectamine 2000 (Invitro-
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gen) with mammalian pcDNA3 expression plasmids encod-
ing full-length, C-terminal FLAG-tagged, wild type or dou-
bly mutated (C669A/H675A) HDAC4 proteins. Cells were
harvested after 24 h, as described previously (18). The double
mutation was introduced using the QuikChange mutagene-
sis kit (Stratagene).
To investigate the effects of a cell-permeable HDAC4 inhib-
itor, HEK293 cells were stably transfected to enable the doxy-
cyclin-inducible expression of full-length HDAC4-FLAG, as
described previously (33). HEK293 cells transfected with an
empty vector and induced with doxycyclin were used as a con-
trol. Cells were maintained at 37 °C, 5% CO2 in DMEM supple-
mented with 10% fetal bovine serum and, when 90% confluent,
were inducedwith 1g/ml doxycyclin 20 hprior to the addition
of inhibitor. A cell-permeable trifluoromethylketone inhibitor
closely resembling the co-crystallized TFMK was added to the
medium at 10 M final concentration for 4 h, after which cells
were harvested.
Immunoprecipitation of HDAC4-FLAG and Analysis of Its
Association with N-CoRHDAC3—All cells were harvested in
ice-cold PBS, homogenized, and sonicated in lysis buffer con-
taining 20mMHepes, pH 7.9, 0.25mMEDTA, 10% glycerol, 250
mM KCl, 0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl fluo-
ride, and a protease inhibitor mixture (Roche Applied Science),
followed by a 1-h incubation at 4 °C. Soluble whole-cell extracts
were obtained by centrifugation. HDAC4-F protein complexes
were immunoprecipitated on anti-FLAG M2 affinity gel
(Sigma) and eluted in buffer containing 50 mM Hepes, pH 7.4,
100 mM KCl, 5% glycerol, and 0.01% Triton X-100 in the pres-
ence of 100 mg/ml 3 FLAG peptide (Sigma). Purified
HDAC4-F wild type and mutant protein concentrations were
normalized via a Western blot developed using an anti-FLAG
horseradish peroxidase-conjugated antibody. Finally, the co-
immunoprecipitation of endogenous HDAC3 with HDAC4-
FLAG was evaluated by Western blotting using a rabbit anti-
HDAC3 antibody and developed
using an anti-rabbit horseradish
peroxidase-conjugated antibody
(Upstate Biotechnology).
RESULTS
Identification of Novel HDAC4
Inhibitors—We previously found
that HDAC4 had only marginal
activity against acetylated lysine-
containing peptides, whereas an
active site mutant (H976Y), which
we refer to as the GOFHDAC4, was
active on these molecules (18).
Moreover, we discovered one mole-
cule, a trifluoroacetamide, on which
both full-length and the catalytic
domain of HDAC4 were highly
active when tested in the same
deacetylation assay previously
reported. In contrast, this com-
pound was a poor substrate for class
I and IIb HDACs, including
HDAC1, -3, and -6 (18) and the GOF HDAC4cd (Fig. 1, A and
B).Within amedicinal chemistry effort, we have now identified
two compounds that inhibit HDAC4 in the hydrolysis of the
trifluoroacetamide substrate with IC50 values in the nanomolar
range (Fig. 1, B and C). The two inhibitors have identical scaf-
folds but differ in their zinc-chelating groups: a hydroxamic
acid (HA) or a TFMK. The inhibitory potency of these mole-
cules on the GOF HDAC4 mutant was also evaluated using an
acetamide version of the same substrate (Fig. 1, B and C).
Structure Determination of Inhibitor-bound HDAC4 Cata-
lytic Domains—To gain structural insights into class IIa
HDACs and the mechanism of their inhibition, we crystallized
the WT and GOF HDAC4cds in complex with the TFMK and
HA inhibitors. The four complexes crystallized in the same
conditions and gave similar crystals (see Table S1). We initially
solved the structure of the WT HDAC4cd-TFMK complex by
the single anomalous dispersion method. This structure was
then used as the starting model to solve and refine all the struc-
tures reported here (see “Experimental Procedures”).
Global Structure Description—The HDAC4cd-inhibitor
complex structures are essentially identical (C coordinate
root mean square deviation 0.3 Å) except for differences in
the interactions with inhibitors. The HDAC4cd core exhibits a
layered -- fold, with a central parallel -sheet of eight
-strands (Fig. 2A) and overall is similar to HDAC8 (C coor-
dinate root mean square deviation 2.2 Å). The catalytic zinc
ion, located in the center of the catalytic domain, is bound by
the inhibitors (see Fig. S1). In addition, as observed in
HDAC8, two potassium ions are proximal to the active site,
coordinated by residues largely conserved among HDACs
(Figs. 2A and 3) (20, 21).
A Conserved Class IIa Structural Zinc-binding Domain—A
novel feature distinguishing HDAC4cd from class I HDACs is
the presence of a structural zinc ion holding together two pro-
tein segments that depart from the core of themolecule (Fig. 2).
FIGURE 1.Catalytic activity and inhibitionofHDAC4wild type andmutants.A, the full-lengthWTHDAC4 is
highly active on the trifluoroacetamide substrate, whereas the H976Ymutant is inactive. RFU, relative fluores-
cence units. B, top, the substrate, comprising an acetylated lysine side chain (where R represents CH3) or the
trifluoroacetamide version (where R represents CF3). Bottom, the inhibitor; R represents CF3 for the trifluorom-
ethylketone (TFMK) or NH-OH for the hydroxamic acid (HA). C, potency of TFMK and HA inhibitors for WT and
GOF HDAC4cd proteins.
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The first segment forms a 17-amino acid loop (L1-2) and
contributes three zinc ligands: His665, Cys667, and His678 (Fig. 2
and Table S2). The second segment is a 35-residue insertion
(6-7-3-4) forming a helix-turn-helix motif followed by a
-hairpin containing at its tip a fourth zinc ligand, Cys751.
Notably, these four zinc ligands are strictly conserved in all class
IIa enzymes but are absent in other HDACs (Fig. 3). The pres-
ence of the structural zinc-binding domain and additional dif-
ferences in loop structures result in HDAC4 having a more
accessible active site than HDAC8 or HDAH (Fig. 2, A–C).
Moreover, the water-filled tunnel proposed to enable release of
the acetate reaction product in HDAC8, HDLP, and HDAH is
not formed (19, 21, 22).
Analysis of the crystal packing revealed that an intermolecu-
lar disulfide bond had formed between Cys669, lying within the
structural zinc-binding domain (Fig. 2), and Cys700 from a
neighboring molecule. To exclude
the possibility that disulfide forma-
tionmight have affected the interac-
tion of the inhibitors with active site
residues, we also solved the struc-
tures of WT and GOF HDAC4cd
containing either a C669A/C700A
double mutation or a C700A single
mutation in complexwith the inhib-
itors. The structures of the mutants
were identical to those of the corre-
sponding nonmutated WT and
GOF proteins except for the struc-
tural zinc-binding domain that was
now disordered (i.e. no electron
density was observed). Therefore,
we conclude that in the HDAC4cd-
inhibitor complexes, this domain is
flexible and that the intermolecular
disulfide bond had previously
locked it in place. Hereafter, for
each of the WT and GOF inhibitor
complexes, only the higher resolu-
tion structures are described, inde-
pendently of the presence of cys-
teine mutations (Table S1).
Analyses of the Inhibitor-bound
HDAC4 Active Sites and Compari-
son with Class I and IIb HDACs—In
theHDAC4cd structures, the inhib-
itors occupy the same position but
establish different interactions with
the zinc ion. In the complexwith the
TFMK, the inhibitor is in its
hydrated form and employs both
oxygens for coordinating the cata-
lytic zinc ion (Fig. 4A and Table S2).
Notably,NMRanalyses showed that
the TFMK is already 70–90%
hydrated in solution (27). In con-
trast, in the WT HDAC4cd-HA
complex, the inhibitor binds the
catalytic zinc ion in a monodentate fashion, with its carbonyl
oxygen replacing one of the TFMK -OH groups and a zinc-
bound water molecule (W1 in Fig. 4A and Table S2) substitut-
ing the other.
In the two complexes, the trifluoromethyl group of the
TFMK and the hydroxyl group of theHApoint toward a pocket
formed by Pro800, Gly811, Phe812, Glu973, and Gly974. In partic-
ular, the trifluoromethyl group makes van der Waals contacts
with the Pro800 pyrrolidine ring (Fig. 4). The residues compos-
ing this pocket are largely conserved among class II HDACs.
However, a similar pocket is also formed in HDAC8 (class I)
despite the sequence differences and lack of proline residues
(Fig. 3). This is achieved through replacement of the HDAC4
Pro800 side chain with the indole ring of HDAC8 Trp141 and
a different arrangement of the HDAC8 polypeptide chain in
the region corresponding to HDAC4 residues Arg798–Gly801
FIGURE 2. The inhibitor-bound HDAC4 catalytic domain. A, HDAC4cd bound to the TFMK inhibitor (sticks);
Protein Data Bank code 2VQJ. Zinc and potassium ions are shown asmagenta and gray spheres, respectively.
The four residues coordinating the structural zinc ion are shown (sticks). B, a superposition of TFMK-bound
HDAC4cd (blue/red) and HDAC8 (yellow). Each -helix and -strand of HDAC4 has a structural counterpart in
HDAC8, except for 6, 7, 3, 4, and 18. The C terminus of HDAC8 coincides with the end of 19, such that
20 and 21 are also absent fromHDAC8. Loop L18 of HDAC8 is much shorter than loop 1-2 of HDAC4. The
yellow dotted line indicates HDAC8 residues missing due to disorder. C, a superposition of TFMK-bound
HDAC4cd (blue/red) and HDAH (green). Loop L1H of HDAH ismuch longer than loop1-2 of HDAC4. Both L1H
and L18 loops turn inward toward the catalytic site. Themajor differences with HDAH occur in this loop and in
the 6-7-3-4 region and in the longer C terminus of HDAC4.
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(Fig. 4B). This region is relatively well conserved among class
I HDACs, but Trp141 is replaced by Leu in HDAC1, HDAC2,
and HDAC3, probably resulting in a larger pocket (Figs. 3
and 4B).
An additional difference between HDAC8, HDLP, and
HDAH and the inhibitor-boundHDAC4cd structures is that in
the latter, one side of the inhibitor is solvent-exposed. In par-
ticular, a pocket, only partially filled by a watermolecule (W2 in
Fig. 4A), is present between the zinc-bound carbonyl/-OH
group of the inhibitors and the main chain of Gly975-His976.
This space is entirely occupied by the side chain of Tyr306
(HDAC8 numbering) in HDAC8, HDLP, and HDAH, whereas
the side chain of the corresponding residue in HDAC4, His976,
points toward the solvent and away from the inhibitor (Figs. 4A
and 5, A and B). These differences in the HDAC active sites
could be exploited for the design of class-selective inhibitors.
FIGURE 3. Multiple sequence alignment of HDAC catalytic domains. Shown is a structure-based multiple sequence alignment, made using the ESPript
program, of HDACs from classes I, IIa, IIb, and IV and the bacterial HDAC-like proteins, HDLP and HDAH. Secondary structure elements are shown for the
TFMK-bound HDAC4cd structure; numbering is for wild type HDAC4. Blue triangles, binds structural zinc ion in inhibited and inhibitor-free structures; red
triangles, only binds structural zinc ion in the inhibited protein; black triangles, only binds structural zinc ion in the inhibitor-free protein; blue circles, binds both
the catalytic zinc ion (via side chains) and potassium ion-1 (via backbone); open circle, binds the catalytic zinc ion (via side chain); pink circles, binds only
potassium ion-1 via side chains (Asp838 and Ser861) or backbone (Leu862); black star, “gain-of-function” residue; black square, mutation to Ala reduces activity.
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Structural Basis for the Low Enzymatic Activity of Class IIa
HDACs toward Acetylated Lysines—In class I and IIb HDACs,
the hydroxyl group of Tyr306 has been proposed to stabilize the
transition state by hydrogen bonding with the oxyanion inter-
mediate (19). Instead, in HDAC4cd, the side chain of the cor-
responding residue, His976, is rotated away from the active site,
and a water molecule, W2, forms hydrogen bonds with the
backbone nitrogen of Gly975 and an oxygen atom of the inhib-
itor (2.43 Å to OH1 of the TFMK, 3.0 Å to the carbonyl of the
HA) (Fig. 5, A and B). The latter interaction is reminiscent of
the one established in HDAC8 by the Tyr306 hydroxyl group
with the carbonyl oxygen of theHA inhibitor (20, 21, 24). Thus,
in HDAC4, W2 could form a similar bond with the reaction
intermediate and contribute, albeit less efficiently, to its stabi-
lization and to catalysis.
The “outward” orientation of theHis976 side chain in theWT
HDAC4cd structures and a limited stabilization of the transi-
tion state may explain the low activity of class IIa HDACs on
acetylated lysines. This hypothesis is supported by the 3.3 Å
resolution structure of theGOFHDAC4cd-HA complex show-
ing repositioning of the Tyr976 side chain into the “inward”
HDAC8-like orientation (Fig. 5C and Fig. S3). In this structure,
the position of the Tyr976 hydroxyl group exhibits angles and
distances (2.9 Å) enabling hydrogen bonding with the HA
carbonyl oxygen, thus explaining the class I-like activity levels
of this mutant.
The structure of the GOFHDAC4cd-TFMK complex (Table
S1) provides further insight into our activity data and the
observed inhibition profiles (Fig. 1). In this complex, the Tyr976
side chain is rotated away from the active site, like the corre-
spondingHis976 in theWTHDAC4cd structures, and thewater
moleculeW2 forms a hydrogen bond with the inhibitor (Fig. 5,
B and D). The different orientation of Tyr976 in the HA- and
TFMK-bound structures reflects the different steric effects
imposed by the two inhibitors. Indeed, a model based on the
structure of the GOF HDAC4cd-TFMK complex suggests that
the hydroxyl group of Tyr976 in the inward position would be
too close (2.0 Å) to the trifluoromethyl group of the inhibitor.
A steric hindrance between the Tyr976 hydroxyl group and the
trifluoromethyl group is in agreement with the low enzymatic
activity of GOF HDAC4 and of class I HDACs toward the tri-
fluoroacetamide substrate (Fig. 1) (18), despite these proteins
being highly active on the canonical acetylated lysine substrate.
Of note, in a recent structure of HDAH bound to a trifluorom-
ethylketone inhibitor, the corresponding tyrosine is found in
the inward position pointing toward the inhibitor, which occu-
pies two alternative positions (23). Differences in length and
flexibility of neighboring loops L1-2 and L9-15 (Fig. 2, B
and C) probably constrain this tyrosine rotamer in the HDAH
enzyme but not in the GOF HDAC4cd.
Active Site Binding and the Conformation of the Structural
Zinc-binding Domain—To obtain additional insight into the
HDAC4 enzymatic mechanism, we attempted to crystallize
WT and GOF HDAC4cd proteins in the presence of sub-
strates (Fig. 1B). Only the GOF HDAC4cd incubated with
the trifluoroacetamide substrate yielded crystals that dif-
fracted to sufficient resolution (Table S1). Although the
crystals grew only after preincubation with the substrate, the
resulting structure showed no electron density for the sub-
strate, suggesting that it had been hydrolyzed, thus yielding
an inhibitor-free structure.
When compared with the inhibitor-bound structures, the
inhibitor-free structure shows considerable differences in the
conformation of the structural zinc-binding domain (Figs. 6, A
and B, and S2). In particular, the two loops harboring the resi-
dues coordinating the structural zinc ion moved 10–20 Å
toward the active site, resulting in a much greater similarity to
the substrate-bound HDAC8 structure (Fig. 6C) (24). This
“closed” conformation of the structural zinc-binding domain
also results in the formation of the tunnel proposed to allow
product release in other HDACs and not formed in the inhibi-
tor-bound HDAC4cd structures.
The comparison of the inhibitor-free and inhibitor-bound
HDAC4cd structures provides an explanation for the differ-
ences in the conformation of the structural zinc-binding
domain (Fig. 6). In fact, superposition of the two structures
reveals that in the “closed” conformation, the inhibitor would
clash with the structural zinc binding domain, thus promoting
the “open” conformation. In addition, the structural compari-
FIGURE 4. Interactions of HDAC4cd with inhibitors. A, interactions of the
TFMK (yellow carbons) and HA (green carbons) with HDAC4; the complex
structures have PDB codes 2VQJ and 2VQM, respectively. Red spheres, water
molecules. The surface around the protein is shown for the TFMK-bound
HDAC4cd. B, superposition of HDAC4cd (cyan) bound to TFMK (sticks and
surface)withHDAC8 (yellow) andhomology-modeledHDAC1 (magenta). Res-
idues surrounding the trifluoro group are labeled. Cyan spheres, C atoms.
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son reveals a switch in the ligation scheme of the structural zinc
ion (Fig. 6, A and B, and Table S2) with His665 and His678 in the
inhibitor-bound structure being replaced by Cys669 and His675
in the inhibitor-free structure (Fig. 3). Notably, the latter two
residues are also conserved only in class IIa HDACs. This vari-
ability in the structural zinc ion coordination is supported by
thiol alkylation experiments in which we observed that even in
mild reaction conditions, all of the cysteines involved in zinc
binding as well as those exposed to the solvent were alkylated,
whereas the cysteines buried in the structure did not react (see
“Experimental Procedures”). A loose coordination of the struc-
tural zinc ion may be required to allow conformational flexibil-
ity of the structural zinc-binding domain and might play a role
in the regulation of HDAC4 function.
Role of the HDAC4 Structural Zinc-binding Domain in Cat-
alytic Activity and Binding to the HDAC3N-CoR Co-repressor
Complex—Aconsequence of the refolding of the structural zinc
binding domain, as observed in the absence of inhibitor, is the
positioning of Asp759 at the border of the active site (Fig. 6B).
Moreover, in this inhibitor-free structure, Asp759 forms a
hydrogen bond with the backbone nitrogen of a neighboring
crystallographically related molecule. This interaction is remi-
niscent of the one established between the structurally con-
served HDAC8 residue Asp101 and the backbone nitrogens of a
peptidic substrate (Fig. 6C) (24). Similarly toHDAC8,mutation
of Asp759 to Ala in the GOF HDAC4cd resulted in a large
decrease in deacetylase activity, indicating an involvement of
this residue in substrate recognition (Fig. 7A).
To better define the role of the structural zinc-binding
domain, wemutated into alanineCys669 andHis675, two ligands
of the structural zinc ion in the
inhibitor-free GOF HDAC4cd.
These mutations are expected to
affect the coordination of the struc-
tural zinc ion and ultimately desta-
bilize the structure of the entire
subdomain. The resulting double
mutant protein was soluble but
inactive (Fig. 7A). Likewise, the
GOF HDAC4cd C669A/C700A
double mutant showed reduced
activity, whereas the C700A single
mutant showed an activity equal to
that of GOF HDAC4cd (data not
shown). These results are in line
with our structural studies. In fact,
Cys700 is solvent-exposed and far
away from both the active site and
the structural zinc-binding domain
in both the inhibitor-bound and
inhibitor-freeHDAC4cd structures,
and therefore its mutation to ala-
nine is expected not to have an
affect on theHDAC4 catalytic activ-
ity. In contrast, Cys669 is involved in
zinc chelation in the inhibitor-free
form of the enzyme, and, similarly
to the double mutant C669A/
H675A, the single mutation C669A is likely to affect the coor-
dination of the structural zinc ion. Together, these data support
an involvement of the zinc-binding domain in substrate recog-
nition and/or enzyme activity.
It has been previously shown that HDAC4 forms amultipro-
tein complex with the N-CoRHDAC3 co-repressor complex
(17). To explore the role of the structural zinc-binding domain
on the association of HDAC4 with the HDAC3N-CoR com-
plex, we transfected HEK293 cells with either full-length
FLAG-tagged wild type HDAC4 or with the C669A/H675A
HDAC4 double mutant. The proteins were then immunopre-
cipitated, and Western blotting analysis was used to reveal
additionally associated, co-purified proteins. In these experi-
ments, we found that the endogenousHDAC3N-CoR complex
co-purified with wild type HDAC4 but not with the double
mutant protein (Fig. 7B), indicating that a properly folded
structural zinc-binding domain is required for the formation of
the repressor complex.
The HDAC4cd structures reported here suggest that the
zinc-binding domain is flexible and that binding of some active
site inhibitors and/or substrates may affect its conformation.
Thus, we also explored if, similarly to the C669A/H675A dou-
ble mutant, an active site inhibitor may also interfere with the
HDAC4HDAC3N-CoR interaction. Indeed, addition to cells
of a cell-permeable class IIa selective structural analogue of the
TFMK inhibitor prevented the formation of the complex (Fig.
7C). Therefore, some active site inhibitors may inhibit both the
HDAC4 catalytic activity and interfere with the recruitment of
the HDAC3N-CoR co-repressor complex.
FIGURE 5. The active sites of HDAC4 and HDAC8. A, the active site of HDAC8 (yellow side chains) bound to a
hydroxamic acid inhibitor (light brown) from Protein Data Bank entry 1W22. B, WT HDAC4cdwith bound TFMK
(yellow carbons) (Protein Data Bank code 2VQQ) and superposed HA (green carbons) (Protein Data Bank code
2VQM). The active site closely resembles HDAC8. C, the active site of GOF HDAC4cd with HA bound (Protein
Data Bank code 2VQV); Tyr976 adopts the inward, class I-like conformation. D, the active site of GOF HDAC4cd
with TFMK bound (Protein Data Bank code 2VQO); Tyr976 adopts an outward conformation.
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DISCUSSION
Class IIa HDACs have been implicated in several biological
processes. To date, however, no histone or protein substrates
have been identified for class IIa HDACs, and only a low cata-
lytic activity toward acetylated lysines has been reported (18).
Here we describe the inhibitor-bound and inhibitor-free struc-
tures of the class IIa HDAC4 catalytic domain and of an active-
site mutant with enhanced catalytic activity toward acetylated
lysine substrates. The structures and accompanying mutagen-
esis data provide insights into class IIa HDAC catalytic activity,
design of class-selective HDAC inhibitors, and regulation of
HDAC4 function.
The HDAC4cd structures reported here revealed the pres-
ence of an unexpected, class IIa-specific, structural zinc-bind-
ing domain. This domain adopted a different conformation in
the inhibitor-free (“closed”) and in the inhibitor-bound
(“open”) forms of the enzyme. In the initial structures of the
HDAC4cd-inhibitor complexes, the zinc-binding domain was
locked in the “open” position by
an intermolecular disulfide bond
between Cys669, in the zinc-binding
domain, and Cys700 from a neigh-
boring molecule. However, muta-
tion of Cys700 to Ala resulted in a
lack of electron density for the zinc-
binding domain, presumably due to
its increased mobility, demonstrat-
ing that this domain is intrinsically
conformationally flexible.
The inhibitor-free structure
resembles the substrate-bound
HDAC8 and is likely to represent
the active conformation of the
enzyme. In particular, Asp759,
which is located far from the active
site in the HDAC4cd-inhibitor
complex, is positioned at the rim of
the active site in the inhibitor-free
structure. The latter position of
Asp759 is equivalent to that of
Asp101 in HDAC8, a residue impli-
cated in positioning the substrate
(24). Moreover, similarly to the
D101A mutant in HDAC8, muta-
tion of Asp759 to Ala results in a
strong decrease in HDAC4 enzy-
matic activity. Of note, mutation
into alanine of two of the ligands
of the structural zinc ion in the in-
hibitor-free structure, Cys669 and
His675, also resulted in a catalytically
inactive protein, further supporting
a role of this domain in substrate
binding.
An intriguing difference between
the inhibitor-free and inhibitor-
bound HDAC4cd structures is the
exchange of two of the ligands of the
structural zinc ion. In support of the crystallographic data, our
alkylation experiments also suggest the zinc ion is only weakly
bound. The concomitance of a loose zinc coordination scheme
and the involvement of Cys669 in an intermolecular disulfide
bond might have stabilized in the inhibitor-bound HDAC4cd
structure a zinc ligation scheme that might otherwise only be
transiently formed. It remains to be seen if such variability in
zinc coordination plays a role in the regulation ofHDAC4 func-
tion in vivo.
It has been shown that HDAC4 associates with the
N-CoRHDAC3 co-repressor complex (17). To assess the role
of the structural zinc-binding domain in the association of
HDAC4 with N-CoRHDAC3, we evaluated the ability of full-
length wild type and C669A/H675A mutant HDAC4-FLAG
proteins to form the ternary complex. In these experiments,
the wild type protein co-purified with the N-CoRHDAC3
complex, whereas the double mutant did not. Thus, the
HDAC4 structural zinc-binding domain has a key role for
FIGURE6.Conformational flexibility of the structural zinc-binding domain and role in substrate bind-
ing. A, the active site of TFMK-bound WT HDAC4cd showing the original structural zinc-binding scheme
(cyan sticks). B, the new conformation of the zinc-binding region in the inhibitor-free GOF HDAC4cd
structure (Protein Data Bank code 2VQW). C, a structural comparison of the active sites of the inhibitor-free
GOF HDAC4cd structure (blue/red) and HDAC8 (yellow) bound to an acetylated lysine peptidic substrate
(gray). The blue and yellow spheres representing the C atoms of HDAC4 Glu677 and HDAC8 Lys33, respec-
tively, illustrate how this inhibitor-free HDAC4 structure has a more closed active site due to the new
conformation of the 1-2 loop.
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N-CoRHDAC3 binding, and it has to be properly folded for
the formation of a stable ternary complex.
Comparison of the inhibitor-bound and inhibitor-free
HDAC4cd structures suggested that some inhibitorsmay affect
the conformation of the structural zinc-binding domain by
sterically interfering with the closed conformation of the zinc
binding domain. In addition, our mutagenesis data point to a
role of the structural zinc-binding domain for the association of
HDAC4withN-CoRHDAC3. Thus, we investigated the effects
of active site inhibitors on the formation of the HDAC4N-
CoRHDAC3 complex. Strikingly, the same disruptive effect
observed for the C669A/H675A double mutant was obtained
by the addition to cells of a cell-permeable class IIa selective
trifluoromethylketone inhibitor. Thus, inhibitor binding may
destabilize the structural zinc-binding domain and conse-
quently the association of HDAC4 with N-CoRHDAC3 in
cells. Together, these data point to a key role of the structural
zinc-binding domain in the recruitment of HDAC4 partner
proteins in repressor complexes. Importantly, our data suggest
that someHDAC4 active site inhibitors may not only inhibit its
enzymatic activity but may also interfere with the recruitment
of the class I HDAC3 to the promoters of HDAC4-regulated
genes.
While thismanuscript was under review, it was reported that
HDAC4 Cys669 and Cys667 can be alkylated in cells, form
intramolecular disulfide bonds in response to reactive oxygen
species, and be reduced by Trx1 (thioredoxin 1) (34). Impor-
tantly, the same authors found that formation of the disulfide
bond causes shuttling of HDAC4 from the nucleus to the cyto-
plasm. These findings are in agreement with ours and further
support our proposal that in HDAC4 the structural zinc ion is
only loosely coordinated and has key regulatory roles. In addi-
tion, our structural data provide an explanation for the obser-
vations of Ago et al. (34). Under reducing conditions, Cys669
and Cys667 are involved in the coordination of the structural
zinc ion, whereas under oxidative
conditions, they form a disulfide
bond probably resulting in impaired
zinc binding and alteration of the
conformation of the zinc-binding
domain.
The structures reported here also
provide insights into the catalytic
activity of HDACs. Existing struc-
tural data on HDLP, HDAH, and
HDAC8 enzymes have generated a
plausible catalytic mechanism for
lysine deacetylation (19). This
mechanism is consistent with our
HDAC4cd-inhibitor structures.
Thus, the HDAC4cd-HA complex
mimics the preintermediate state
with a zinc-bound water molecule
(W1) aptly positioned for nucleo-
philic attack on the carbonyl carbon
of the substrate, whereas the com-
plex with the hydrated TFMK
resembles the reaction intermediate
formed after nucleophilic attack by this water molecule. How-
ever, in WT HDAC4, there is no protein atom in a position
corresponding to the Tyr306 hydroxyl group of HDAC8 that
could stabilize the reaction intermediate. Instead, the side chain
of the structurally equivalent His976 is rotated away from the
active site, and a water molecule (W2) appears to functionally
replace Tyr306. These structural differences may account for
the strongly reduced activity of the class IIa HDACs toward
acetylated lysines. The water molecule is probably a less effi-
cient transition state stabilizer than the tyrosine hydroxyl group
due to its faster exchange with the solvent and its lower hydro-
gen bond donating potential.
Our model is supported by the structure of the GOF
HDAC4cd-HA complex, where the Tyr976 side chain points
inwards, as do the equivalent tyrosines in class I and IIb
HDACs. This tyrosine is likely to adopt a similar position in the
presence of the reaction intermediate, thus resulting in its sta-
bilization and the greatly enhanced catalytic activity of GOF
HDAC4cd. Consistently, the HA inhibitor is 30-fold more
potent on the GOF than on WT HDAC4, probably due to the
favorable interactions of the inhibitor carbonyl and hydroxyl
oxygens with the Tyr976 hydroxyl group in the GOF mutant.
Together, these data provide a molecular framework for
understanding the marginal activity of class IIa HDACs on
acetylated lysines and suggest that these enzymes might act
on intrinsically more reactive substrates. Interestingly, it has
been shown recently that mutation of the corresponding
active site Tyr to Phe in the bacterial class IIb homologue
HDAH results in an enzyme with a preference for acetylester
substrates rather than acetamides (35). However, a similar
preference has not been reported for class IIa HDACs to
date. Alternatively, a specific, yet unidentified, cofactor may
be required for HDAC4 activation.
Our structures are consistent with the TFMK being a more
potent inhibitor ofWTHDAC4cd than is theHA (Fig. 1C). The
FIGURE 7.Role of theHDAC4 structural zinc-bindingdomain.A, activities on the acetamide substrate of the
GOF HDAC4cd protein, the GOF HDAC4cd D759A mutant, and the GOF HDAC4cd C669A/H675A mutant.
B, full-length HDAC4 proteins (WT and C669A/H675Amutant; top) were immunopurified and probed byWest-
ern blotting for HDAC3 (bottom). HDAC3 did not co-purifywith themutant protein. C, HDAC3 did not co-purify
with full-length WT HDAC4 when expressed in the presence of a cell-permeable class IIa-specific trifluorom-
ethylketone inhibitor, as shown by Western blotting.
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TFMK is hydrated and binds the catalytic zinc ion in a bidentate
fashion, whereas the HA inhibitor makes only one bond to the
zinc ion (Fig. 4A). In the structures of HDAC8, hydroxamate
compounds bind the zinc ion using a bidentate chelation (Fig.
5A). It is likely that the monodentate binding of the inhibitor in
theHDAC4cd-HA complex was favored due to steric restraints
and the lack of interaction with an active site tyrosine as found
in class I or IIb-like HDACs. A second determinant of the dif-
ference in potency is that the trifluoro moiety fills a pocket in
proximity of Pro800. Such interactions are greatly reduced in
the complex with the HA. Similarly, sequence alignments and
modeling suggest that the trifluoromethyl binding pocket
would be larger in the HDAC1, -2, and -3 enzymes, thus form-
ing fewer favorable contacts. Consistently, trifluoromethylk-
etone compounds typically display 10–100-fold greater inhibi-
tion of class II HDACs than of class I HDACs (27). Thus, the
differences in the size of the pocket around Pro800, together
with the additional space generated in class IIa HDACs by the
outward position of theHis976 side chain, could be exploited for
the design of improved class-selective inhibitors.
While this manuscript was being submitted, the structure of
the HDAC7 catalytic domain alone and in complex with sub-
eroylanilide hydroxamic acid and trichostatin Awas published.
These structures closely resemble the “closed” inhibitor-free
HDAC4cd structure (C coordinate root mean square devia-
tion0.9 Å). Differently from the inhibitors used in our study,
the more flexible suberoylanilide hydroxamic acid and trichos-
tatin A capping groups do not clash with the structural zinc
binding domain and therefore do not interferewith the “closed”
conformation of the structural zinc-binding subdomain. In
addition, in HDAC7cd, the His976 side chain adopts the same
“outward” position observed in the WT HDAC4cd structure,
further confirming that this is a general feature of class IIa
HDACs.
In conclusion, we have shown that despite the overall sim-
ilarity with class I HDACs, the class IIa enzymes present
several novel features. Important differences were observed
in the active sites that are relevant for the catalytic mecha-
nism and inhibitor specificities. We have also identified an
unexpected structural zinc-binding domain conserved only
in class IIa enzymes. Our structural and mutagenesis data
reveal a flexibility of this domain, with direct consequences
on the boundaries of the enzyme active site. More impor-
tantly, we show that the structural zinc-binding domain has
a key role for the association of HDAC4 with N-CoR and
HDAC3 and therefore for the recruitment of these proteins
to HDAC4 repressor complexes.
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